216 related articles for article (PubMed ID: 22740690)
1. X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the β-subunit of succinyl-CoA synthetase (SUCLA2).
Bishop DF; Tchaikovskii V; Hoffbrand AV; Fraser ME; Margolis S
J Biol Chem; 2012 Aug; 287(34):28943-55. PubMed ID: 22740690
[TBL] [Abstract][Full Text] [Related]
2. Regulation and tissue-specific expression of δ-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias.
Peoc'h K; Nicolas G; Schmitt C; Mirmiran A; Daher R; Lefebvre T; Gouya L; Karim Z; Puy H
Mol Genet Metab; 2019 Nov; 128(3):190-197. PubMed ID: 30737140
[TBL] [Abstract][Full Text] [Related]
3. Arg452 substitution of the erythroid-specific 5-aminolaevulinate synthase, a hot spot mutation in X-linked sideroblastic anaemia, does not itself affect enzyme activity.
Furuyama K; Harigae H; Heller T; Hamel BC; Minder EI; Shimizu T; Kuribara T; Blijlevens N; Shibahara S; Sassa S
Eur J Haematol; 2006 Jan; 76(1):33-41. PubMed ID: 16343269
[TBL] [Abstract][Full Text] [Related]
4. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.
To-Figueras J; Ducamp S; Clayton J; Badenas C; Delaby C; Ged C; Lyoumi S; Gouya L; de Verneuil H; Beaumont C; Ferreira GC; Deybach JC; Herrero C; Puy H
Blood; 2011 Aug; 118(6):1443-51. PubMed ID: 21653323
[TBL] [Abstract][Full Text] [Related]
5. GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia.
Daher R; Mansouri A; Martelli A; Bayart S; Manceau H; Callebaut I; Moulouel B; Gouya L; Puy H; Kannengiesser C; Karim Z
Mol Genet Metab; 2019 Nov; 128(3):342-351. PubMed ID: 30660387
[TBL] [Abstract][Full Text] [Related]
6. Anti-Correlation between the Dynamics of the Active Site Loop and C-Terminal Tail in Relation to the Homodimer Asymmetry of the Mouse Erythroid 5-Aminolevulinate Synthase.
Na I; Catena D; Kong MJ; Ferreira GC; Uversky VN
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29958424
[TBL] [Abstract][Full Text] [Related]
7. Molecular expression, characterization and mechanism of ALAS2 gain-of-function mutants.
Tchaikovskii V; Desnick RJ; Bishop DF
Mol Med; 2019 Jan; 25(1):4. PubMed ID: 30678654
[TBL] [Abstract][Full Text] [Related]
8. Molecular expression and characterization of erythroid-specific 5-aminolevulinate synthase gain-of-function mutations causing X-linked protoporphyria.
Bishop DF; Tchaikovskii V; Nazarenko I; Desnick RJ
Mol Med; 2013 Mar; 19(1):18-25. PubMed ID: 23348515
[TBL] [Abstract][Full Text] [Related]
9. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia.
Bekri S; May A; Cotter PD; Al-Sabah AI; Guo X; Masters GS; Bishop DF
Blood; 2003 Jul; 102(2):698-704. PubMed ID: 12663458
[TBL] [Abstract][Full Text] [Related]
10. Human Erythroid 5-Aminolevulinate Synthase Mutations Associated with X-Linked Protoporphyria Disrupt the Conformational Equilibrium and Enhance Product Release.
Fratz EJ; Clayton J; Hunter GA; Ducamp S; Breydo L; Uversky VN; Deybach JC; Gouya L; Puy H; Ferreira GC
Biochemistry; 2015 Sep; 54(36):5617-31. PubMed ID: 26300302
[TBL] [Abstract][Full Text] [Related]
11. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts.
Cotter PD; May A; Fitzsimons EJ; Houston T; Woodcock BE; al-Sabah AI; Wong L; Bishop DF
J Clin Invest; 1995 Oct; 96(4):2090-6. PubMed ID: 7560104
[TBL] [Abstract][Full Text] [Related]
12. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations.
Ducamp S; Kannengiesser C; Touati M; Garçon L; Guerci-Bresler A; Guichard JF; Vermylen C; Dochir J; Poirel HA; Fouyssac F; Mansuy L; Leroux G; Tertian G; Girot R; Heimpel H; Matthes T; Talbi N; Deybach JC; Beaumont C; Puy H; Grandchamp B
Hum Mutat; 2011 Jun; 32(6):590-7. PubMed ID: 21309041
[TBL] [Abstract][Full Text] [Related]
13. Effect of 5-aminolevulinic acid on erythropoiesis: a preclinical in vitro characterization for the treatment of congenital sideroblastic anemia.
Fujiwara T; Okamoto K; Niikuni R; Takahashi K; Okitsu Y; Fukuhara N; Onishi Y; Ishizawa K; Ichinohasama R; Nakamura Y; Nakajima M; Tanaka T; Harigae H
Biochem Biophys Res Commun; 2014 Nov; 454(1):102-8. PubMed ID: 25450364
[TBL] [Abstract][Full Text] [Related]
14. Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia.
Furuyama K; Sassa S
J Clin Invest; 2000 Mar; 105(6):757-64. PubMed ID: 10727444
[TBL] [Abstract][Full Text] [Related]
15. X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley.
Cotter PD; Rucknagel DL; Bishop DF
Blood; 1994 Dec; 84(11):3915-24. PubMed ID: 7949148
[TBL] [Abstract][Full Text] [Related]
16. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations.
Campagna DR; de Bie CI; Schmitz-Abe K; Sweeney M; Sendamarai AK; Schmidt PJ; Heeney MM; Yntema HG; Kannengiesser C; Grandchamp B; Niemeyer CM; Knoers NV; Swart S; Marron G; van Wijk R; Raymakers RA; May A; Markianos K; Bottomley SS; Swinkels DW; Fleming MD
Am J Hematol; 2014 Mar; 89(3):315-9. PubMed ID: 24166784
[TBL] [Abstract][Full Text] [Related]
17. 5-aminolevulinate synthase: catalysis of the first step of heme biosynthesis.
Hunter GA; Ferreira GC
Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):102-10. PubMed ID: 19268008
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia.
Morimoto Y; Chonabayashi K; Kawabata H; Okubo C; Yamasaki-Morita M; Nishikawa M; Narita M; Inagaki A; Nakanishi K; Nagao M; Takaori-Kondo A; Yoshida Y
Blood Adv; 2022 Feb; 6(4):1100-1114. PubMed ID: 34781359
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia.
Kaneko K; Furuyama K; Fujiwara T; Kobayashi R; Ishida H; Harigae H; Shibahara S
Haematologica; 2014 Feb; 99(2):252-61. PubMed ID: 23935018
[TBL] [Abstract][Full Text] [Related]
20. Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP).
Ducamp S; Schneider-Yin X; de Rooij F; Clayton J; Fratz EJ; Rudd A; Ostapowicz G; Varigos G; Lefebvre T; Deybach JC; Gouya L; Wilson P; Ferreira GC; Minder EI; Puy H
Hum Mol Genet; 2013 Apr; 22(7):1280-8. PubMed ID: 23263862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
